Xintela AB publishes Annual Report 2025

Xintela AB (publ) announces that the company’s annual report for 2025 is published on the company’s website www.xintela.se and is attached to this announcement. Link to the annual report: https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela (XINT) is a publicly-traded clinical-stage biopharma company, […]

Xintela AB Year-end Report 2025

Summary of the year-end reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupForth quarter 2025Income amounted to TSEK 415 (1,090).Loss before tax totalled TSEK 17,343 (loss: 11,712).Loss per share was SEK 0.02 (loss: 0.02). Full year 2025Income amounted to TSEK 2,282 (4,215).Loss before tax totalled TSEK 50,158 (loss: 41,534).Loss per share […]

Xintela AB Interim Report January – September 2025

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupThird quarter 2025Income amounted to TSEK 855 (2,822).Loss before tax totalled TSEK 10,035 (loss: 8,049).Loss per share was SEK 0.01 (loss: 0.01). First nine month of 2025Income amounted to TSEK 1,867 (3,125).Loss before tax totalled TSEK 32,816 (loss: […]

Xintela AB Interim Report January – June 2025

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupSecond quarter 2025Income amounted to TSEK 872 (4).Loss before tax totalled TSEK 12,119 (loss: 10,400).Loss per share was SEK 0.02 (loss: 0.02). First half year 2025Income amounted to TSEK 1,012 (303).Loss before tax totalled TSEK 22,780 (loss: 21,773).Loss […]

Xintela AB Interim Report January – March 2025

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupFirst quarter 2025Income amounted to TSEK 140 (299).Loss before tax totalled TSEK 10,427 (loss: 10,997).Loss per share was SEK 0.02 (loss: 0.02). The Parent companyFirst quarter 2025Income amounted to TSEK 140 (299).Loss before tax totalled TSEK 8,574 (loss: 9,688). Significant […]

Xintela AB publishes Annual Report 2024

Xintela AB (publ) announces that the company’s annual report for 2024 is published on the company’s website www.xintela.se and is attached to this announcement. Link to the annual report: https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell […]

Xintela AB Year-end Report 2024

Summary of the year-end report The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupForth quarter 2024Income amounted to TSEK 1,090 (78).Loss before tax totalled TSEK 11,712 (loss: 12,175).Loss per share* was SEK 0.02 (loss: 0.03). Full year 2024Income amounted to TSEK 4,215 (78).Loss before tax totalled TSEK 41,534 (loss: 58,367).Loss […]

Xintela AB Interim Report January – September 2024

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupThird quarter 2024Income amounted to TSEK 2,822 (0).Loss before tax totalled TSEK 8,049 (loss: 11,953).Loss per share was SEK 0.01 (loss: 0.02). First nine month 2024Income amounted to TSEK 3,125 (0).Loss before tax totalled TSEK 29,821 (loss: 46,192).Loss […]

Xintela AB Interim Report January – June 2024

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. THE GROUPSecond quarter 2024Income amounted to TSEK 4 (0).Loss before tax totalled TSEK 10,400 (loss: 18,401).Loss per share was SEK 0.02 (loss: 0.06). First half year 2024Income amounted to TSEK 303 (0).Loss before tax totalled TSEK 21,773 (loss: 34,244).Loss […]

Xintela AB Interim Report January – March 2024

Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First quarter 2024 for the groupIncome amounted to TSEK 299 (0).Loss before tax totalled TSEK 11,372 (loss: 15,843).Loss per share was SEK 0.02 (loss: 0.05). First quarter 2024 for the parent companyIncome amounted to TSEK 299 (0).Loss before […]